Compare PFO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFO | OVID |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 118.9M |
| IPO Year | N/A | 2017 |
| Metric | PFO | OVID |
|---|---|---|
| Price | $9.56 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 31.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $6.90 | $0.24 |
| 52 Week High | $8.51 | $2.01 |
| Indicator | PFO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 62.84 | 50.28 |
| Support Level | $9.43 | $1.57 |
| Resistance Level | $9.51 | $1.87 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 95.24 | 24.19 |
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.